Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated)

For adults aged 18 to 64 years, the standard dose of the vaccine containing the A/Victoria/4897/2022 (H1N1) antigen is a single 0.5 mL intramuscular injection. This is typically administered once annually, ideally before the onset of peak influenza activity in the community (usually by the end of October in the Northern Hemisphere).

For adults aged 65 years and older, healthcare providers may recommend a 'High-Dose' version. This formulation contains four times the amount of antigen (60 mcg of HA per strain instead of the standard 15 mcg) to compensate for the natural weakening of the immune system that occurs with age (immunosenescence).

The use of this antigen in children depends on the specific vaccine brand and the child's age:

• Children 6 months through 35 months: The dose may be 0.25 mL or 0.5 mL depending on the manufacturer’s instructions. If the child has not been vaccinated previously, a two-dose series (separated by at least 4 weeks) is often required to achieve adequate priming of the immune system.
• Children 3 years through 8 years: A single 0.5 mL dose is standard, unless they have not received at least two doses of trivalent or quadrivalent influenza vaccine prior to July 1 of the current season, in which case two doses are required.
• Children 9 years and older: A single 0.5 mL dose is sufficient.

Renal Impairment

No dosage adjustment is required for patients with renal (kidney) impairment. The antigen does not rely on renal clearance for its activity or elimination.

Hepatic Impairment

No dosage adjustment is required for patients with hepatic (liver) impairment. However, patients with severe end-stage liver disease may have a blunted immune response to the vaccine.

Elderly Patients

As noted, elderly patients often receive a higher concentration of the antigen or an adjuvanted version to ensure protective antibody levels are reached. Standard doses are safe but may be less effective in this demographic.

This medication is administered exclusively by healthcare professionals. Key instructions include:

• Preparation: The vaccine should be shaken well before use to ensure a uniform suspension. It should be inspected visually for particulate matter or discoloration.
• Site: The preferred site is the deltoid muscle of the upper arm. For infants and small children, the anterolateral aspect of the thigh is often used.
• Administration: It must be given intramuscularly. Subcutaneous injection may lead to increased local irritation and a less effective immune response.
• Storage: The vaccine must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). It must NEVER be frozen. Exposure to freezing temperatures destroys the protein structure of the antigen, rendering it useless.

Since this is an annual vaccine, there is no 'missed dose' in the daily sense. However, if you miss the early window for vaccination, you should receive it as soon as possible as long as the influenza virus is still circulating in your community. Vaccination can still be beneficial even in January or later.

An overdose is highly unlikely as the vaccine is administered in single-unit doses by professionals. In the event of an accidental double-dose, the primary risk is an increase in the severity of local injection site reactions (swelling, pain) or systemic symptoms (fever). There is no specific antidote; treatment is supportive (e.g., acetaminophen for fever).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most individuals experience mild reactions following the administration of the A/Victoria/4897/2022 (H1N1) antigen. These are signs that the immune system is responding to the antigen:

• Injection Site Pain: This is the most frequently reported side effect, occurring in up to 65% of recipients. It typically feels like a dull ache in the deltoid muscle and lasts 1 to 2 days.
• Tenderness and Erythema (Redness): The area around the injection may become red or sensitive to touch.
• Fatigue: A general feeling of tiredness or lethargy as the body diverts energy to the immune response.
• Headache: Mild to moderate tension-type headaches are common within the first 24 hours.

• Myalgia (Muscle Aches): Generalized muscle aches throughout the body, similar to a very mild flu.
• Arthralgia (Joint Pain): Stiffness or pain in the joints.
• Low-Grade Fever: A temperature usually below 101°F (38.3°C).
• Chills and Shivering: Often accompanying the fever as the body's internal thermostat resets.
• Nausea: Mild gastrointestinal upset may occur, though it is less common in adults than in children.

• Lymphadenopathy: Swelling of the lymph nodes, particularly under the arm where the vaccine was administered (axillary nodes).
• Syncope (Fainting): This is often a vasovagal response to the needle stick rather than a reaction to the antigen itself, especially in adolescents.
• Urticaria (Hives): A mild allergic skin reaction characterized by itchy, raised welts.

> Warning: Stop taking Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include difficulty breathing, swelling of the throat or tongue, rapid heartbeat, and a sharp drop in blood pressure.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis. The estimated risk is about 1 to 2 additional cases per million doses administered.
• Facial Swelling (Angioedema): Significant swelling around the eyes or lips.
• High Fever: A temperature exceeding 103°F (39.4°C).

There are no known long-term side effects associated with the A/Victoria/4897/2022 (H1N1) antigen. The antigen is cleared from the body within days, and the resulting antibodies are a natural part of the immune system's repertoire. Extensive monitoring by the Vaccine Adverse Event Reporting System (VAERS) has shown that flu vaccines have an excellent long-term safety profile.

No FDA black box warnings exist for Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated). It is generally considered safe for the vast majority of the population, including those with chronic underlying medical conditions.

Report any unusual symptoms to your healthcare provider. If you experience a significant reaction, you or your provider may report it to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Before receiving a vaccine containing the A/Victoria/4897/2022 (H1N1) antigen, it is vital to disclose your full medical history to your healthcare provider. While the vaccine is inactivated and cannot cause influenza, certain underlying conditions may affect the safety or efficacy of the immunization.

No FDA black box warnings for Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: Individuals with a history of severe allergic reaction to any component of the vaccine (including formaldehyde, which is used in the inactivation process, or egg proteins if the vaccine is egg-based) should not receive the product. Most modern flu vaccines are safe for people with egg allergies, but a discussion with an allergist may be warranted for severe cases.
• Guillain-Barré Syndrome (GBS): If you have ever had GBS within 6 weeks of a prior influenza vaccination, the decision to give this vaccine should be based on careful consideration of the potential benefits and risks.
• Acute Febrile Illness: Vaccination should typically be delayed in patients with moderate or severe acute illness, with or without fever. This is to avoid diagnostic confusion between the underlying illness and potential vaccine side effects.
• Altered Immunocompetence: If the vaccine is administered to immunocompromised persons, including those receiving immunosuppressive therapy (such as high-dose steroids or chemotherapy), the expected immune response may not be obtained. You may still be vaccinated, but you must be aware that protection may be lower.

There are no routine lab tests (like blood counts or liver function tests) required after receiving this antigen. However, patients should be observed for at least 15 minutes after vaccination to monitor for immediate allergic reactions or syncope (fainting).

The A/Victoria/4897/2022 (H1N1) antigen has no known effect on the ability to drive or operate heavy machinery. However, if you experience dizziness or a headache after the injection, you should wait until these symptoms resolve before engaging in such activities.

There is no direct interaction between alcohol and the influenza antigen. However, excessive alcohol consumption can suppress the immune system and may theoretically reduce the effectiveness of the vaccine's immune response. It is best to avoid heavy drinking for a few days before and after vaccination.

As this is a single-dose annual injection, 'discontinuation' is not applicable in the way it is for daily medications. If you decide not to receive the annual vaccine in subsequent years, there are no withdrawal symptoms, but you will lose the protective immunity against the updated circulating strains.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would prevent the use of the A/Victoria/4897/2022 (H1N1) antigen. However, it should not be mixed in the same syringe with any other vaccine or medication unless specifically authorized by the manufacturer.

• Immunosuppressive Therapies: Drugs such as cyclosporine, tacrolimus, azathioprine, and various cancer chemotherapies may diminish the immune response to the antigen. The mechanism is a direct reduction in the proliferation of B and T cells. Management involves timing the vaccine during a 'window' of relative immune competence if possible.
• High-Dose Corticosteroids: Patients taking 20 mg or more of prednisone (or equivalent) daily for more than two weeks may have a reduced response.

• Antiviral Medications (Oseltamivir, Zanamivir): While inactivated vaccines like this one do not interact with flu antivirals, the live attenuated nasal spray vaccine should not be administered within 48 hours of stopping antivirals. For the formaldehyde-inactivated antigen, there is no known reduction in efficacy when taken with antivirals.
• Anticoagulants (Warfarin, Heparin): There is no chemical interaction, but the intramuscular injection may cause significant bruising or a hematoma (bleeding under the skin) in patients with bleeding disorders or those on blood thinners. A fine-gauge needle should be used, and firm pressure applied for at least two minutes.

There are no known interactions between the A/Victoria/4897/2022 (H1N1) antigen and food or drink. You may eat and drink normally before and after your vaccination.

There is limited data on interactions with herbal supplements. However, supplements known to have potent immunomodulatory effects (like high-dose Echinacea or Astragalus) should be discussed with a doctor, although they are not currently known to interfere with vaccine efficacy.

• False Positive HIV/HCV Tests: There have been rare reports of transient false-positive results in certain enzyme immunoassays (EIA) for HIV-1, Hepatitis C, and HTLV-1 following influenza vaccination. This is thought to be due to the IgM response to the vaccine cross-reacting with the test antigens. These false positives are usually cleared by more specific confirmatory tests (like the Western Blot).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated) must NEVER be used in the following circumstances:

• Severe Allergic Reaction (Anaphylaxis): Anyone who has had a life-threatening allergic reaction to a previous dose of any influenza vaccine or to any component of the vaccine (e.g., egg protein, formaldehyde, gelatin, or antibiotics used in the manufacturing process like neomycin). The mechanism is an IgE-mediated hypersensitivity that can lead to airway obstruction and circulatory collapse.
• Infants under 6 months of age: The safety and efficacy of this antigen have not been established in infants younger than 6 months. Furthermore, maternal antibodies may interfere with the infant's immune response at this age.

These conditions require a careful risk-benefit analysis by a physician:

• History of Guillain-Barré Syndrome (GBS): If GBS occurred within 6 weeks of a previous flu shot, the risk of recurrence is a concern, though the risk of severe flu complications usually outweighs this risk.
• Moderate or Severe Acute Illness: To avoid confusing symptoms of the illness with vaccine side effects, it is standard practice to wait until the patient has recovered.

Patients who are sensitive to formaldehyde (used in the inactivation process) or certain detergents (like Triton X-100 used to 'split' the virus) may experience localized or systemic allergic reactions. If you have a known contact dermatitis allergy to formaldehyde, you should inform your provider, although the trace amounts in the vaccine are usually too low to trigger a systemic reaction.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza A Virus A/victoria/4897/2022 Ivr-238 (h1n1) Antigen (formaldehyde Inactivated).

Pregnancy Category B/C (Depending on specific brand): Vaccination with the inactivated A/Victoria/4897/2022 (H1N1) antigen is strongly recommended for all pregnant women. Pregnant women are at significantly higher risk for severe complications, hospitalization, and death from H1N1 influenza due to changes in their immune, heart, and lung functions.

• Trimester-specific risks: There is no evidence of increased risk of teratogenicity (birth defects) or miscarriage in any trimester.
• Benefit to Infant: Vaccination during pregnancy provides 'passive immunity' to the newborn. The mother's antibodies cross the placenta and protect the infant for several months after birth, which is critical since infants cannot be vaccinated until they are 6 months old.

It is safe to receive the A/Victoria/4897/2022 (H1N1) antigen while breastfeeding. The inactivated antigen does not enter the breast milk. However, the protective antibodies (IgA) produced by the mother can be passed to the infant through breast milk, providing an additional layer of protection against respiratory infections.

• Approved Age: 6 months and older.
• Special Considerations: Children aged 6 months to 8 years may require two doses if it is their first time being vaccinated. This is necessary to 'prime' their immune system to recognize the H1N1 antigen effectively.

Adults 65 years and older are at the highest risk for flu-related mortality. While the standard dose of the A/Victoria/4897/2022 antigen is safe, the immune response may be weaker. Geriatric patients should ideally receive the 'High-Dose' or 'Adjuvanted' versions of the vaccine to ensure a high enough antibody titer to prevent infection.

Patients with chronic kidney disease (CKD) or those on dialysis are considered high-risk for flu complications and should receive the vaccine. No dose adjustment is needed, as the antigen is not cleared renally.

Patients with cirrhosis or other liver diseases should be vaccinated. While their immune response might be slightly lower than healthy individuals, the safety profile remains unchanged.

> Important: Special populations require individualized medical assessment.

The A/Victoria/4897/2022 (H1N1) antigen is a 'split-virus' or 'subunit' antigen. During manufacturing, the virus is inactivated with formaldehyde and then chemically 'split' using detergents. This releases the internal and surface proteins. The most important of these is Hemagglutinin (HA).

HA is a lectin that mediates the binding of the virus to target cells. By introducing this inactivated HA into the body, the vaccine 'teaches' the immune system to produce antibodies that specifically fit the HA 'key.' If the real virus enters the body, these antibodies bind to the HA, preventing the 'key' from fitting into the cellular 'lock' (sialic acid receptors), thereby neutralizing the virus.

The pharmacodynamic effect is measured by the Hemagglutination Inhibition (HI) antibody titer. A titer of 1:40 or greater is generally considered to be associated with protection from influenza illness in approximately 50% of subjects. The onset of this effect is not immediate; it takes 14-21 days for the body to generate sufficient antibody levels. The duration of protection typically lasts 6 to 12 months, which is why annual revaccination is required.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A |

| Half-life | N/A (Antibodies last months) |

| Tmax | 2-4 weeks (for antibody peak) |

| Metabolism | Cellular Proteolysis |

| Excretion | Phagocytosis/Lymphatic |

The antigen consists of purified proteins. The molecular weight of the Hemagglutinin trimer is approximately 220,000 Daltons. It is soluble in physiological saline and is typically buffered with phosphates to maintain a pH of 6.5 to 7.5. The formaldehyde inactivation process creates methylene cross-links between amino groups in the viral proteins, ensuring the virus is non-infectious.

This agent is classified as a Vaccine, Inactivated, Viral. It is part of the seasonal influenza vaccine group. Unlike live attenuated vaccines, this product contains no live genetic material and cannot undergo reassortment or reversion to virulence.